<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03688828</url>
  </required_header>
  <id_info>
    <org_study_id>BoulardiitoHp2018</org_study_id>
    <nct_id>NCT03688828</nct_id>
  </id_info>
  <brief_title>Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori</brief_title>
  <official_title>The Evaluation of Saccharomyces Boulardii Sachets Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori: a Prospective, Multi-Center Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiaogan Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiaogan First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hubei Aerospace Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The third people's Hospital of Hubei Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anlu Puai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The eradication rate of standard quadruple therapy has become less successful due to low
      compliance and high resistance to the antibiotics. Therefore, it is necessary to develop new
      treatment strategies that increase the eradication rate and reduce adverse effects. The aims
      of this prospective study is to investigate the efficacy of Saccharomyces Boulardii sachets
      for eradication of Hp, compared with standard quadruple therap.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In China, the first-line therapy to treat Helicobacter pylori (Hp) consists of a
      bismuth-based proton pump inhibitor (PPI) and two antibiotics for 14 days. But, eradication
      has become less successful due to low compliance and high resistance to the antibiotics.
      Therefore, it is necessary to develop new treatment strategies that increase the eradication
      rate and reduce adverse effects. Several studies previously suggested that probiotics could
      be effective for improving Hp eradication rate or reducing adverse events with PPI-based
      triple therapy. But, their effect for eradication of Hp is not yet conclusive. And the
      experiments now available about efficacy of Saccharomyces Boulardii were mainly combined with
      triple therapy. The aims of this prospective study is to investigate the efficacy of
      Saccharomyces Boulardii sachets for eradication of Hp, compared with standard quadruple
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Helicobacter pylori eradication</measure>
    <time_frame>6 weeks after treatment initiation</time_frame>
    <description>to investigate the efficacy of Saccharomyces Boulardii sachets for eradication of Hp, compared with standard quadruple therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>2 weeks and 4-12 weeks after treatment initiation</time_frame>
    <description>to investigate the efficacy of Saccharomyces Boulardii sachets for reduction of incidence of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">776</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saccharomyces boulardii + Esomeprazole + Amoxicillin + Clarithromycin + Bismuth potassium citrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadruple Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole + Amoxicillin + Clarithromycin + Bismuth potassium citrate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saccharomyces boulardii</intervention_name>
    <description>500mg bid</description>
    <arm_group_label>Probiotics</arm_group_label>
    <other_name>Brad's yeast powder;Biocodex, Paris, France</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>20mg bid</description>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_label>Quadruple Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>1.0g bid</description>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_label>Quadruple Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>0.5g bid</description>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_label>Quadruple Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth potassium citrate</intervention_name>
    <description>0.22g bid</description>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_label>Quadruple Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Helicobacter pylori infected patients

          -  13C DOB&gt;8

          -  age 22~65

        Exclusion Criteria:

          -  prior Hp eradication therapy including amoxicillin and clarithromycin

          -  previous gastric resection

          -  allergic to the drugs used in this study

          -  previous use of proton pump inhibitors, bismuth, H2 receptor antagonist or
             antibiotics, probiotics within 4 weeks of the study

          -  Patients who were pregnant or lactating

          -  Patients taking NSAIDs, alcoholic or with other serious disease (e.g. hepatopathy,
             heart disease, nephropathy，diabete mellitus, hypertension…) effect the evaluation of
             this study

          -  Can't express the complaint correctly
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bin Cheng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuchong Zhao, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bin Cheng, Doctor</last_name>
    <phone>027-83663334</phone>
    <email>bcheng@tjh.tjmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuchong Zhao, Doctor</last_name>
    <phone>027-83663334</phone>
    <email>zhaoyuchongtj@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical School, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuchong Zhao, Doctor</last_name>
      <phone>13006128635</phone>
      <email>zhaoyuchongtj@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Bin Cheng, Professor</last_name>
      <phone>+86 27 83663595</phone>
      <email>b.cheng@tjh.tjmu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Song MJ, Park DI, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter. 2010 Jun;15(3):206-13. doi: 10.1111/j.1523-5378.2010.00751.x.</citation>
    <PMID>20557362</PMID>
  </reference>
  <reference>
    <citation>Zojaji H, Ghobakhlou M, Rajabalinia H, Ataei E, Jahani Sherafat S, Moghimi-Dehkordi B, Bahreiny R. The efficacy and safety of adding the probiotic Saccharomyces boulardiito standard triple therapy for eradication of H.pylori: a randomized controlled trial. Gastroenterol Hepatol Bed Bench. 2013;6(Suppl 1):S99-S104.</citation>
    <PMID>24834296</PMID>
  </reference>
  <reference>
    <citation>Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010 Nov;32(9):1069-79. doi: 10.1111/j.1365-2036.2010.04457.x. Epub 2010 Sep 16. Erratum in: Aliment Pharmacol Ther. 2010 Dec;32(11-12):1408.</citation>
    <PMID>21039671</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Bin Cheng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Saccharomyces Boulardii</keyword>
  <keyword>Standard Quadruple Therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

